Treatment of cancers having a drug-resistant mesenchymal cell state
AssigneeDana-Farber Cancer Institute, Inc.
InventorsAndrew AGUIRRE, Kevin KAPNER, Kyle EVANS
Life of this patent
Estimating the term…
Abstract
The subject matter disclosed herein is generally directed to methods of treating a tumor capable of an epithelial-to-mesenchymal transition (an EMT cancer) by targeting the mesenchymal cell state. Disclosed are novel gene dependencies in the mesenchymal cell state. Also, disclosed are novel drugs that target the mesenchymal cell state.
Claims22
1-4. (canceled)
A method for treating a subject having a cancer capable of an epithelial-to-mesenchymal transition (an EMT cancer), the method comprising:
- administering to the subject one or more agents capable of inhibiting the expression or activity of CDS2, ELMO2, ITGAV, AP1M1, FERMT2, CHMP4B, PTK2, ITGB5, PRKAR1A, ACTR1A, SRF, ZEB1, MTOR, DNM1L PSMB7, MOB4, TEAD1, DOCK5, ACTR3, BCAR1, UFM1, TIPARP, ILK, RSU1, WWTR1, NCKAP1, ATP6V1C1, MYH9, FOSL1, LIMS1, GNB1, EFR3A, ARHGEF7, WDR7, PKN2, CEMIP2, TEAD1, CTDNEP1, MARK3, VCL, CDC42, BCAR1, EGLN1, UFM1, GPX4, and/or CRK,
- thereby treating the subject having the EMT cancer.
6-35. (canceled)
A method for identifying and treating a subject having a cancer capable of an epithelial-to-mesenchymal transition (an EMT cancer), the method comprising:
- (a) detecting the expression in the cancer of one or more genes identified as positively correlated with CDS2 dependency selected from among PKP3, CDS1, MAL2, ELF3, IRF6, PATJ, CDH1, MAP7, ARHGEF16, ARHGEF5, TNK1, CNKSR1, ARHGAP8, CLDN4, IQANK1, CDH3, OVOL1, C11orf52, GRB7, GRHL2, C6orf132, MARVELD3, ESRP1, MPZL2, CHMP4C, TMEM125, TACSTD2, MYO5B, PRSS22, S100A14, SRP2, CRB3, EPCAM, RAB25, CLBC, TMEM184A, CLDN7, PRSS8, PRRG2, and SFN;
- and
- (b) administering to the subject one or more agents capable of inhibiting CDS2 expression or activity,
- thereby identifying and treating the subject having the EMT cancer.
A method for identifying and treating a subject having a cancer capable of an epithelial-to-mesenchymal transition (an EMT cancer), the method comprising:
- (a) detecting in the subject one or more metabolites identified as negatively correlated with CDS2 dependency, wherein the one or more metabolites is selected from among oxalate, C38.4.PC, AMP, C40.6.PC, C56.5.TAG, C50.0.TAG, trimethylamine.N.oxide, C58.7.TAG, C56.7.TAG, C36.4.PC.A, UMP, C22.1.SM, dCMP, C56.6.TAG, C58.6.TAG, C36.4.PC.B, C58.8.TAG, cytidine, CMP, C38.6.PC, alpha.glycophosphate, arachidonyl_carnitine, C38.5.PC, and C58.8.TAG;
- and
- (b) administering to the subject one or more agents capable of inhibiting CDS2 expression or activity,
- thereby identifying and treating the subject having the EMT cancer.
Dependencies are inferred from the claim text.